Teysuno is named as an intervention in 48 current clinical trials in our China, South Korea, Taiwan, Japan, USA, Germany, France, Spain, Italy, Singapore, UK, India, Belgium, Denmark, Poland, Norway, Turkey, Canada, Brazil and Australia registers. 25 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is The First Affiliated Hospital with Nanjing Medical University (5). The most-studied condition is Gastric Cancer.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gastric Cancer | 11 |
| Biliary Tract Cancer | 4 |
| Gastric Adenocarcinoma | 4 |
| Gastroesophageal Junction Adenocarcinoma | 3 |
| Pancreatic Cancer | 2 |
| Gastric (Stomach) Cancer | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
| Intrahepatic Cholangiocarcinoma (Icc) | 2 |
| Recurrent or Metastatic Nasopharyngeal Carcinoma | 2 |
| Chemotherapy Effect | 2 |
| Stomach Neoplasms | 2 |
| HER2-positive Gastric Cancer | 2 |
| Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | 1 |
| Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | 1 |
| PDAC - Pancreatic Ductal Adenocarcinoma | 1 |
| Pancreas Cancer | 1 |
| Pancreatic Neoplasms | 1 |
| Second Line Treatment | 1 |
| Chemotherapy | 1 |
| Tyrosine Kinase Inhibitor | 1 |
| Previously AG Chemotherapy Treated Pancreatic Cancer | 1 |
| Metastatic Pancreatic Ductal Adenocarcinoma | 1 |
| RCT | 1 |
| Gastric Cancer Metastatic to Regional Lymph Nodes | 1 |
| Locally Advanced Gastric Adenocarcinoma | 1 |
| Locally Advanced Gastric Carcinoma | 1 |
| Intrahepatic Cholangiocarcinoma | 1 |
| Linitis Plastica of Stomach | 1 |
| Phase II, Open-label, Parallel 2-arm, Multi-center | 1 |
| Locally Advanced Esophageal Squamous Cell Carcinoma | 1 |
| Metastatic Gastric Cancer | 1 |
| Unresectable Gastric Carcinoma | 1 |
| Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | 1 |
| Peritoneal Metastasis | 1 |
| Immunotherapy Gastrict Cancer | 1 |
| Immune Checkpoint Inhibitors | 1 |
| Locally Advanced Gastroesophageal Junction Adenocarcinoma | 1 |
| Gastric Cancer (GC) | 1 |
| Adjuvant Chemotherapy | 1 |
| Stage 3 Cancer | 1 |
| Docetaxel | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Liver Neoplasms | 1 |
| Lung Neoplasms | 1 |
| Postoperative Adjuvant Therapy | 1 |
| Maintenance Therapy | 1 |
| Gastroesophageal-junction Cancer | 1 |
| Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 1 |
| Gastric (Cardia, Body) Cancer | 1 |
| Stomach Adenocarcinoma | 1 |
| Locally Advanced | 1 |
| Neoadjuvant Therapy | 1 |
| Pan-tumor | 1 |
| Stomach Neoplasm | 1 |
| Cholangiocarcinoma | 1 |
| Biliary Tract Cancer (BTC) | 1 |
| NSCLC | 1 |
+ 16 more sponsors in the trial list above.
A trial with sites in more than one country appears in each of those registers.
48 current trials in our China, South Korea, Taiwan, Japan, USA, Germany, France, Spain, Italy, Singapore, UK, India, Belgium, Denmark, Poland, Norway, Turkey, Canada, Brazil and Australia registers name Teysuno (also registered as S-1) as a drug or biological intervention, as of the registry sync on 6 October 2026. Completed and withdrawn studies are not counted.
Yes. 25 of the 48 trials are recruiting: 23 with sites in China, 2 with sites in South Korea, 1 with sites in Taiwan and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The First Affiliated Hospital with Nanjing Medical University (5), Sun Yat-sen University (4), Ruijin Hospital (4) and Ono Pharmaceutical Co., Ltd (3), among 31 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Teysuno works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Teysuno works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Teysuno (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 6 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
